Home Premarket Biotech Digest: Is Gilead Undervalued, Oncolytics' Reolysin, Novo Nordisk Reports Results
 

Keywords :   


Premarket Biotech Digest: Is Gilead Undervalued, Oncolytics' Reolysin, Novo Nordisk Reports Results

2015-07-13 18:14:55| Biotech - Topix.net

Gilead Sciences shares have once again seen a pullback in the last three weeks. Since June 24th, the stock is down nearly 7%, presenting another good opportunity to buy.

Tags: results reports novo digest

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
30.06Hurricane Beryl Update Statement
30.06Summary for Hurricane Beryl (AT2/AL022024)
30.06Hurricane Beryl Graphics
30.06Hurricane Beryl Forecast Discussion Number 8
30.06Hurricane Beryl Public Advisory Number 8
30.06Hurricane Beryl Wind Speed Probabilities Number 8
30.06Hurricane Beryl Forecast Advisory Number 8
30.06Weekly Recap: Rockline Wins WOW Innovation Award, Hospeco Purchases Nuance Solutions & More
More »